Acarix AB ("Acarix" or the "Company") has received declarations of intent to exercise Warrants of series TO 3 (the "Warrants") from a number of major holders of Warrants. The declarations of intent encompass approximately 36.8 million Warrants, corresponding to approximately 40.7 percent of the total number of Warrants.
Acarix CEO Aamir Mahmood comments: “We once again receive strong support from our existing shareholders, something we greatly appreciate and value. We have implemented many changes during the recent quarters, and have many ongoing processes, which will materialize in the coming quarters. It is gratifying that our major shareowners acknowledge this. We are thankful and look forward to managing this trust.”
Life Science Invest Fund CEO Jan Poulsen comments: “As a long-term investor we at LSIF strive to build value through investing in life science companies in the early commercial phase with products that hold great potential and can have a huge positive impact for patients and society. We believe that the CADScor System is unique and one of these products. We fully support the many organizational and focus changes initiated by CEO Aamir Mahmood, and we therefore do not hesitate to declare that it is our intention to continue to support Acarix by subscribing to the very significant number of TO3 that we have acquired. As long-term investors we are committed and engaged owners, and we follow our investment plan.”
Acarix has received declarations of intent from a number of major holders of Warrants, including Life Science Invest Fund 1 ApS, Microtech Software AS, Mikael Thorén with family, and Anton Rehnström regarding the exercise of Warrants. The declarations of intent encompass approximately 36.8 million Warrants, corresponding to approximately 40.7 percent of the total number of Warrants. The Warrants have an exercise period from and including Wednesday September 11, 2024, up to and including Wednesday, September 25, 2024, and each Warrant entitles the holder to subscribe for one new share. The exercise price will be set at 70 percent of the volume-weighted average price ("VWAP") during the measurement period August 23 – September 6, 2024, but no less than SEK 0.25 and no more than SEK 0.50.
Complete terms and conditions for the Warrants are available on the Company's website and in the prospectus prepared by the Board of Directors of Acarix in connection with the Rights Issue. The prospectus is available on the Company's website. It is also available on the Swedish Financial Supervisory Authority's website www.fi.se.
Exercise of warrants
Trustee-registered Warrants
If the warrant holder has their Warrants in a share depository, in an investment savings account (Sw. ISK), or an endowment insurance (Sw. Kapitalförsäkring) (trustee-registered holdings), subscription and payment will take place with the nominee, who will provide further instructions on the procedure for exercising the Warrants. Warrant holders should contact their nominee well in advance for further instructions regarding the exercise of Warrants, as different nominees have different processing times.
Directly registered Warrants (VP account)
Application is made via a subscription form available on Carnegie Investment Bank AB (publ)'s website www.carnegie.se and Acarix's website www.acarix.com. A pre-printed subscription form has been sent to directly registered warrant holders. Payment is made according to instructions on the application form. Both the subscription form and payment must be received by Carnegie Investment Bank AB (publ) by September 25, 2024.
IMPORTANT INFORMATION
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Acarix in any jurisdiction, neither from Acarix nor from someone else.
This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.
This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zeeland, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
